{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T10:42:09Z","timestamp":1648723329427},"reference-count":40,"publisher":"Elsevier BV","issue":"4","content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2014,6]]},"DOI":"10.1016\/j.bcp.2014.03.011","type":"journal-article","created":{"date-parts":[[2014,3,30]],"date-time":"2014-03-30T13:47:04Z","timestamp":1396187224000},"page":"464-476","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Structural determinants of the catalytic inhibition of human topoisomerase II\u03b1 by salicylate analogs and salicylate-based drugs"],"prefix":"10.1016","volume":"89","author":[{"given":"Jason T.","family":"Bau","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ebba U.","family":"Kurz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcp.2014.03.011_bib0005","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/nrc2608","article-title":"DNA topoisomerase II and its growing repertoire of biological functions","volume":"9","author":"Nitiss","year":"2009","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.bcp.2014.03.011_bib0010","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1017\/S003358350800468X","article-title":"DNA topoisomerases: harnessing and constraining energy to govern chromosome topology","volume":"41","author":"Schoeffler","year":"2008","journal-title":"Q Rev Biophys"},{"key":"10.1016\/j.bcp.2014.03.011_bib0015","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1126\/science.1127196","article-title":"A topoisomerase IIbeta-mediated dsDNA break required for regulated transcription","volume":"312","author":"Ju","year":"2006","journal-title":"Science"},{"key":"10.1016\/j.bcp.2014.03.011_bib0020","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1126\/science.287.5450.131","article-title":"DNA topoisomerase IIbeta and neural development","volume":"287","author":"Yang","year":"2000","journal-title":"Science"},{"key":"10.1016\/j.bcp.2014.03.011_bib0025","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1038\/nrc2607","article-title":"Targeting DNA topoisomerase II in cancer chemotherapy","volume":"9","author":"Nitiss","year":"2009","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.bcp.2014.03.011_bib0030","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1021\/cb300648v","article-title":"Drugging topoisomerases: lessons and challenges","volume":"8","author":"Pommier","year":"2013","journal-title":"ACS Chem Biol"},{"key":"10.1016\/j.bcp.2014.03.011_bib0035","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S0163-7258(03)00058-5","article-title":"Catalytic topoisomerase II inhibitors in cancer therapy","volume":"99","author":"Larsen","year":"2003","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.bcp.2014.03.011_bib0040","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S0167-4781(98)00133-X","article-title":"Catalytic inhibitors of DNA topoisomerase II","volume":"1400","author":"Andoh","year":"1998","journal-title":"Biochim Biophys Acta (BBA) \u2013 Gene Struct Expr"},{"key":"10.1016\/j.bcp.2014.03.011_bib0045","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1038\/nrclinonc.2013.195","article-title":"Treatment-related cardiotoxicity in survivors of childhood cancer","volume":"10","author":"Lipshultz","year":"2013","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.bcp.2014.03.011_bib0050","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1016\/S1470-2045(10)70204-7","article-title":"Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomised, multicentre trial","volume":"11","author":"Lipshultz","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.bcp.2014.03.011_bib0055","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1016\/j.ejca.2011.03.022","article-title":"The low incidence of secondary acute myelogenous leukaemia in children and adolescents treated with dexrazoxane for acute lymphoblastic leukaemia: a report from the Dana-Farber Cancer Institute ALL Consortium","volume":"47","author":"Vrooman","year":"2011","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.bcp.2014.03.011_bib0060","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.bcp.2010.10.009","article-title":"Sodium salicylate is a novel catalytic inhibitor of human DNA topoisomerase II alpha","volume":"81","author":"Bau","year":"2011","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.bcp.2014.03.011_bib0065","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1124\/mol.113.088963","article-title":"Salicylate, a catalytic inhibitor of topoisomerase II, inhibits DNA cleavage and is selective for the \u03b1 isoform","volume":"85","author":"Bau","year":"2014","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.bcp.2014.03.011_bib0070","doi-asserted-by":"crossref","first-page":"13207","DOI":"10.1016\/S0021-9258(17)36820-5","article-title":"Acetylation of human prostaglandin endoperoxide synthase-2 (cyclooxygenase-2) by aspirin","volume":"269","author":"Lecomte","year":"1994","journal-title":"J Biol Chem"},{"key":"10.1016\/j.bcp.2014.03.011_bib0075","doi-asserted-by":"crossref","first-page":"13371","DOI":"10.1073\/pnas.222543099","article-title":"Cyclooxygenase-3 (COX-3): filling in the gaps toward a COX continuum?","volume":"99","author":"Warner","year":"2002","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.bcp.2014.03.011_bib0080","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1039\/c1fo10128e","article-title":"Natural salicylates: foods, functions and disease prevention","volume":"2","author":"Duthie","year":"2011","journal-title":"Food Funct"},{"key":"10.1016\/j.bcp.2014.03.011_bib0085","doi-asserted-by":"crossref","first-page":"2891","DOI":"10.1021\/jf058158w","article-title":"Salicylic acid content of spices and its implications","volume":"54","author":"Paterson","year":"2006","journal-title":"J Agric Food Chem"},{"key":"10.1016\/j.bcp.2014.03.011_bib0090","doi-asserted-by":"crossref","first-page":"53272","DOI":"10.1074\/jbc.M406879200","article-title":"Doxorubicin activates ATM-dependent phosphorylation of multiple downstream targets in part through the generation of reactive oxygen species","volume":"279","author":"Kurz","year":"2004","journal-title":"J Biol Chem"},{"key":"10.1016\/j.bcp.2014.03.011_bib0095","first-page":"137","article-title":"ICE bioassay. Isolating in vivo complexes of enzyme to DNA","volume":"95","author":"Subramanian","year":"2001","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.bcp.2014.03.011_bib0100","series-title":"Goodman & Gillman's the pharmacological basis of therapeutics","article-title":"Analgesic\u2013antipyretic and anti-inflammatory agents: pharmacology of gout","author":"Burke","year":"2009"},{"key":"10.1016\/j.bcp.2014.03.011_bib0105","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1038\/nrm3228","article-title":"All tangled up: how cells direct, manage and exploit topoisomerase function","volume":"12","author":"Vos","year":"2011","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.bcp.2014.03.011_bib0110","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.chembiol.2010.04.012","article-title":"DNA topoisomerases and their poisoning by anticancer and antibacterial drugs","volume":"17","author":"Pommier","year":"2010","journal-title":"Chem Biol"},{"key":"10.1016\/j.bcp.2014.03.011_bib0115","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1016\/j.saa.2010.08.078","article-title":"Spectroscopic studies of the interaction of aspirin and its important metabolite, salicylate ion, with DNA, A\u00b7T and G\u00b7C rich sequences","volume":"77","author":"Bathaie","year":"2010","journal-title":"Spectrochim Acta A: Mol Biomol Spectrosc"},{"key":"10.1016\/j.bcp.2014.03.011_bib0120","doi-asserted-by":"crossref","first-page":"2362","DOI":"10.1021\/np200292u","article-title":"Catalytic inhibition of eukaryotic topoisomerases I and II by flavonol glycosides extracted from Vicia faba and Lotus edulis","volume":"74","author":"Tselepi","year":"2011","journal-title":"J Nat Prod"},{"key":"10.1016\/j.bcp.2014.03.011_bib0125","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1021\/tx8000785","article-title":"Dietary polyphenols as topoisomerase II poisons: B ring and C ring substituents determine the mechanism of enzyme-mediated DNA cleavage enhancement","volume":"21","author":"Bandele","year":"2008","journal-title":"Chem Res Toxicol"},{"key":"10.1016\/j.bcp.2014.03.011_bib0130","first-page":"159","article-title":"Protection against adriamycin cytotoxicity and inhibition of DNA topoisomerase II activity by 3,4-dihydroxybenzoic acid","volume":"23","author":"De Graff","year":"2003","journal-title":"Int J Oncol"},{"key":"10.1016\/j.bcp.2014.03.011_bib0135","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1093\/mutage\/ger006","article-title":"Green tea constituents (\u2212)-epigallocatechin-3-gallate (EGCG) and gallic acid induce topoisomerase I- and topoisomerase II-DNA complexes in cells mediated by pyrogallol-induced hydrogen peroxide","volume":"26","author":"L\u00f3pez-L\u00e1zaro","year":"2011","journal-title":"Mutagenesis"},{"key":"10.1016\/j.bcp.2014.03.011_bib0140","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/978-1-60761-340-4_4","article-title":"Cleavage of plasmid DNA by eukaryotic topoisomerase II","volume":"582","author":"Bandele","year":"2009","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.bcp.2014.03.011_bib0145","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1021\/tx700434v","article-title":"(\u2212)-Epigallocatechin gallate, a major constituent of green tea, poisons human type II topoisomerases","volume":"21","author":"Bandele","year":"2008","journal-title":"Chem Res Toxicol"},{"key":"10.1016\/j.bcp.2014.03.011_bib0150","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1002\/chem.19970030115","article-title":"Organic fluorine hardly ever accepts hydrogen bonds","volume":"3","author":"Dunitz","year":"1997","journal-title":"Chem Eur J"},{"key":"10.1016\/j.bcp.2014.03.011_bib0155","doi-asserted-by":"crossref","first-page":"5061","DOI":"10.1021\/jm100112j","article-title":"A medicinal chemist's guide to molecular interactions","volume":"53","author":"Bissantz","year":"2010","journal-title":"J Med Chem"},{"key":"10.1016\/j.bcp.2014.03.011_bib0160","doi-asserted-by":"crossref","first-page":"11693","DOI":"10.1073\/pnas.90.24.11693","article-title":"Selectivity of nonsteroidal antiinflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase","volume":"90","author":"Mitchell","year":"1993","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.bcp.2014.03.011_bib0165","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1111\/j.1365-2125.1989.tb03562.x","article-title":"Concentration\u2013response relationships for salicylate-induced ototoxicity in normal volunteers","volume":"28","author":"Day","year":"1989","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.bcp.2014.03.011_bib0170","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1172\/JCI0214955","article-title":"Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes","volume":"109","author":"Hundal","year":"2002","journal-title":"J Clin Invest"},{"key":"10.1016\/j.bcp.2014.03.011_bib0175","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1093\/carcin\/bgl220","article-title":"Aspirin activates the NF-kappaB signalling pathway and induces apoptosis in intestinal neoplasia in two in vivo models of human colorectal cancer","volume":"28","author":"Stark","year":"2007","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.bcp.2014.03.011_bib0180","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1111\/j.2042-7158.1958.tb10316.x","article-title":"The hydrolysis of acetylsalicylic acid from aqueous suspension","volume":"10","author":"James","year":"1958","journal-title":"J Pharm Pharmacol"},{"key":"10.1016\/j.bcp.2014.03.011_bib0185","series-title":"Aspirin and related drugs","author":"Rainsford","year":"2004"},{"key":"10.1016\/j.bcp.2014.03.011_bib0190","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1146\/annurev.phyto.050908.135202","article-title":"Salicylic acid, a multifaceted hormone to combat disease","volume":"47","author":"Vlot","year":"2009","journal-title":"Annu Rev Phytopathol"},{"key":"10.1016\/j.bcp.2014.03.011_bib0195","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1104\/pp.99.3.799","article-title":"Salicylate, a new plant hormone","volume":"99","author":"Raskin","year":"1992","journal-title":"Plant Physiol"},{"key":"10.1016\/j.bcp.2014.03.011_bib0200","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1136\/jcp.54.7.553","article-title":"Salicylic acid in the serum of subjects not taking aspirin. Comparison of salicylic acid concentrations in the serum of vegetarians, non-vegetarians, and patients taking low dose aspirin","volume":"54","author":"Blacklock","year":"2001","journal-title":"J Clin Pathol"}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295214001981?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295214001981?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T10:20:59Z","timestamp":1648722059000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295214001981"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,6]]},"references-count":40,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2014,6]]}},"alternative-id":["S0006295214001981"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2014.03.011","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2014,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Structural determinants of the catalytic inhibition of human topoisomerase II\u03b1 by salicylate analogs and salicylate-based drugs","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2014.03.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}